Skip to main content

Table 1 Properties of KPC-positive clinical isolates and transformant strains. Isolates were collected from 29 patients in the time period January 2009-June 2010

From: KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December 2011: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units

Sample ID

Hospital unit

carbapenemase

β-lactamase

molecular typing

MIC (mg/L)

  

KPC

VIM

TEM

SHV

CTX

OXA

MLST

PFGE

ERIC

IPM

MER

CTX

CAZ

FEP

SXT

GEN

AMK

TGC

13

SAH-ICU

2

1

1

12

nd

9

147

A

a

≥16

≥16

≥64

≥64

≥64

≥320

4

32

2

20

SAH-ICU

2

1

1

12

nd

9

147

A

a

≥16

≥16

≥64

≥64

≥64

≥320

4

≥64

2

39

SAH-ICU

2

nd

1

nd

nd

9

147

A

a

≥16

≥16

≥64

≥64

≥64

40

≤1

≤2

2

40

SAH-ICU

2

nd

1

nd

nd

9

147

A

a

≥16

≥16

32

16

32

40

≤1

≤2

2

Top10-41

          

8, 2

2, 0.5

≥64

4

2

≤20

≤1

≤2

≤0.5

42

SAH-ICU

2

nd

1

12

nd

9

147

A

a

≥16

≥16

32

16

32

40

≤1

≤2

2

46

SAH-ICU

2

nd

1

12

nd

9

147

A

a

≥16

≥16

32

16

≥64

40

≤1

≤2

2

49

SAH-ICU

2

1

nd

nd

nd

9

147

A

a

≥16

≥16

32

16

≥64

40

≤1

≤2

2

65

SAH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

4

8

≥64

8

≥320

2

≥64

2

68

SAH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

4

32

≥64

8

≥320

4

≥64

2

69

SAH-ICU

2

nd

1

12

nd

9

147

A

a

≥16

≥16

32

16

≥64

40

≤1

≤2

2

Top10-69

          

8, 3

1, 1

≥64

4

2

≤20

≤1

≤2

≤0.5

74

SAH-ICU

2

nd

nd

nd

nd

nd

147

A

a

≥16

≥16

≥64

≥64

≥64

≥320

4

≥64

2

35

TH-ICU

3

nd

1

nd

nd

9

258

B

b

≥16

8

≥64

≥64

16

≥320

≥16

8

2

Top10-35

          

8, 2

1, 0.75

≥64

4

2

≤20

≤1

≤2

≤0.5

44

TH-ICU

3

nd

1

nd

nd

9

258

B

b

8

8

8

≥64

16

≥320

≥16

16

2

Top10-44

          

8, 1.5

1, 0.5

≥64

4

2

≤20

≤1

≤2

≤0.5

45

TH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

2

≥64

≥64

16

≥320

≥16

8

2

48

TH-ICU

3

nd

nd

nd

nd

9

258

B

b

≥16

8

≥64

≥64

16

≥320

≥16

8

2

53

TH-ICU

3

nd

1

nd

nd

9

258

B

b

≥16

8

≥64

≥64

16

≥320

≥16

≥64

2

Top10-53

          

8, 2

2, 0.38

≥64

4

2

≤20

≤1

≤2

≤0.5

63

TH-ICU

3

nd

1

nd

nd

9

258

B

b

≥16

8

≥64

≥64

32

≥320

≥16

16

2

71

TH-ICU

3

nd

1

11

nd

9

258

B

b

4

2

16

≥64

8

≥320

≥16

8

2

72

TH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

4

16

≥64

8

≥320

4

≥64

4

12

TH-SU

 

nd

nd

nd

nd

nd

527

C

c

≥16

≤0.25

≤1

≤1

≤1

≥320

≤1

4

2

Top10-12

          

8, 2

2, 0.5

≥64

4

2

≤20

≤1

≤2

≤0.5

14

TH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

8

8

≥64

8

≥320

2

≥64

4

19

TH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

2

8

≥64

≥64

≥320

2

≥64

2

8

TH-MU

3

nd

1

11

nd

9

258

B

b

≥16

2

8

≥64

16

≥320

4

≥64

2

17

TH-MU

3

nd

1

11

nd

9

258

B

b

≥16

4

8

≥64

8

≥320

4

≥64

4

18

TH-MU

3

nd

1

11

nd

9

258

B

b

4

2

16

≥64

8

≥320

4

≥64

4

4

TH-LTCU

3

nd

1

11

nd

9

258

B

b

4

2

8

≥64

8

≥320

4

≥64

2

7

TH-LTCU

3

nd

1

11

15

9

37

D

b

≥4

2

≥64

≥64

≥64

≥320

8

≤2

2

Top10-7

          

8, 3

2, 1

≥64

4

2

≤20

≤1

≤2

≤0.5

21

TH-ICU

3

nd

1

11

nd

9

258

B

b

≥16

≥16

≥64

≥64

≥64

≥320

4

≥64

1

64

TH-ICU

3

nd

1

nd

nd

9

258

B

b

≥16

8

8

≥64

16

≥320

≥16

16

2

Top10-64

          

8, 2

1, 0.38

≥64

4

2

≤20

≤1

≤2

≤0.5

Top10

          

≤1, 0.25

≤0.25, 0.32

≤1

≤1

≤1

≤20

≤1

≤2

≤0.5

  1. IPM = imipenem; MER = meropenem; CTX = cefotaxime; CAZ = ceftazidime; FEP = cefepime; SXT = sulfamethoxazole-trimethoprim; GEN = gentamicin; AMK = amikacin; TGC = tigecycline. Transformed E. coli strains are indicated as Top10 and the number corresponding to the clinical sample from which the plasmid was obtained.
  2. In transformed Top10 strains, MIC values of imipenem and meropenem were obtained by Vitek (first MIC value) and E-test (second MIC value in italics).